Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside

16 Apr 2018

Abstract excerpt

Individuals with breast and ovarian cancer susceptibility gene 1 (BRCA1) or BRCA2 germline mutations have a significantly increased lifetime risk for breast and ovarian cancers. BRCA-mutant cancer cells have abnormal homologous recombination (HR) repair of DNA. In these tumors, the base excision repair (BER) pathway is important for cell survival. The poly(adenosine diphosphate-ribose) polymerase (PARP) enzymes...

Topics

Join the communities discussing this publication.

BRCA gene mutations in cancer
DNA Repair Mechanisms
PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 29660759
DOI: 10.1002/cncr.31307

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedsidePMID 29660759Read ↗

Advances in PARP inhibitors for the treatment of breast cancer.Semantic proximity Read ↗

PARP inhibitors in breast cancer: BRCA and beyond.Semantic proximity Read ↗

PARP inhibitors in the management of breast cancer: current data and future prospects.Semantic proximity Read ↗

PARP inhibitors: Synthetic lethality in the clinicSemantic proximity Read ↗

Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.Semantic proximity Read ↗

Targeting the BRCA1/2 Tumor SuppressorsSemantic proximity Read ↗

Breast Cancer Predisposition Genes and Synthetic Lethality.Semantic proximity Read ↗

PARP Inhibitors in Breast and Ovarian CancerSemantic proximity Read ↗

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and ResistanceSemantic proximity Read ↗

Therapeutic advances and application of PARP inhibitors in breast cancerSemantic proximity Read ↗

The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethalitySemantic proximity Read ↗

The potential of PARP inhibitors in genetic breast and ovarian cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.